Compare Relay Therapeutics Inc. Common Stock (RLAY) vs Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) (YMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Relay Therapeutics Inc. Common Stock vs Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) — how do they compare? Relay Therapeutics Inc. Common Stock trades at $17.23 (market cap $3.81B), while Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) trades at $8.59 (market cap $9.09B). The key difference: Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) is far larger — about 2.4× Relay Therapeutics Inc. Common Stock's market cap, and Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) pays a 3.84% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Relay Therapeutics Inc. Common Stock for 5 Days and Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) for 0 Days on average.
| RLAY | YMM | |
|---|---|---|
Market Cap | $3.81B | $9.09B |
Volume | 1,706,150 | 10,124,674 |
Sector | Health | Technology |
52-Week High | $20.75 | $13.30 |
52-Week Low | $6.05 | $7.54 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $2.93B | $5.57B |
Dividend Yield | — | 3.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Relay Therapeutics (RLAY) trades at $17.36, down 3.45% today, with technical indicators showing bearish momentum. The company remains in clinical-stage development with negative profitability metrics, including a -2,763.64% net income margin and -$276.48M net loss for 2025. Recent Q2 2026 earnings missed expectations with a loss of $0.41 per share, though the company continues advancing its oncology pipeline with Phase 3 trials planned for 2027.
Despite unanimous analyst buy ratings and a $26.25 consensus price target representing 51% upside, RLAY faces significant execution risk as a pre-revenue biotech. The stock's bearish technical setup and persistent cash burn require careful risk management, though institutional accumulation and AI-driven drug discovery platform provide long-term potential.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Relay Therapeutics Inc. Common Stock
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →About Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares)
Full Truck Alliance Co. Ltd. operates a digital freight-matching platform in China, connecting shippers with truckers for cargo transport across varying distances and load types.
Read more on YMM →
